Richard F. Pops Sells 30,000 Shares of Alkermes PLC (ALKS) Stock
Alkermes PLC (NASDAQ:ALKS) Director Richard F. Pops sold 30,000 shares of the company’s stock in a transaction on Tuesday, November 29th. The shares were sold at an average price of $56.98, for a total value of $1,709,400.00. Following the transaction, the director now directly owns 638,962 shares in the company, valued at $36,408,054.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Alkermes PLC (NASDAQ:ALKS) traded down 2.14% on Wednesday, hitting $56.83. The stock had a trading volume of 1,390,825 shares. Alkermes PLC has a one year low of $27.14 and a one year high of $80.71. The stock’s market capitalization is $8.64 billion. The firm’s 50 day moving average is $52.71 and its 200-day moving average is $47.68.
Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The business had revenue of $180.20 million for the quarter, compared to the consensus estimate of $186.39 million. Alkermes PLC had a negative return on equity of 12.75% and a negative net margin of 36.92%. The business’s revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. Equities research analysts expect that Alkermes PLC will post ($0.20) earnings per share for the current fiscal year.
ALKS has been the topic of several recent analyst reports. Cowen and Company reissued a “buy” rating on shares of Alkermes PLC in a research report on Friday, September 23rd. Citigroup Inc. upped their price target on Alkermes PLC from $44.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, September 27th. Morgan Stanley reissued a “sell” rating and set a $41.00 price target on shares of Alkermes PLC in a research report on Friday, September 2nd. Zacks Investment Research lowered Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 14th. Finally, Credit Suisse Group AG upped their target price on Alkermes PLC from $52.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, October 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $61.64.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALKS. S&CO Inc. raised its position in Alkermes PLC by 4.3% in the second quarter. S&CO Inc. now owns 9,800 shares of the company’s stock valued at $424,000 after buying an additional 400 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of Alkermes PLC by 23.6% in the second quarter. LS Investment Advisors LLC now owns 2,846 shares of the company’s stock worth $123,000 after buying an additional 544 shares during the period. IBM Retirement Fund raised its stake in shares of Alkermes PLC by 1.2% in the second quarter. IBM Retirement Fund now owns 15,193 shares of the company’s stock worth $657,000 after buying an additional 177 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Alkermes PLC during the second quarter worth approximately $264,000. Finally, Independent Portfolio Consultants Inc. purchased a new stake in shares of Alkermes PLC during the second quarter worth approximately $179,000. Hedge funds and other institutional investors own 95.97% of the company’s stock.
Alkermes PLC Company Profile
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.